BA
PACB icon

Bridgewater Associates’s Pacific Biosciences PACB Stock Holding History

Bridgewater Associates’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$173K Buy
+102,761
New +$149K ﹤0.01% 993

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bridgewater Associates's PACB Position: Q2 2026 in Review

Bridgewater Associates opened a new position in Pacific Biosciences (PACB) in Q2 2026: 102,761 shares worth $173K. The stake represents ﹤0.01% of the portfolio and ranks #993 among its holdings.

223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Bridgewater Associates held 102,761 shares of Pacific Biosciences worth $173K as of Q2 2026.
  • Pacific Biosciences was a new Bridgewater Associates position in Q2 2026.
  • Pacific Biosciences made up ﹤0.01% of Bridgewater Associates's portfolio in Q2 2026, its #993 holding.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.